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Background: The role of platelets for mediating closure of the ductus arteriosus in 
human preterm infants is controversial. Especially, the effect of low platelet counts on 
pharmacological treatment failure is still unclear.
Methods: In this retrospective study of 471 preterm infants [<1,500 g birth weight (BW)], 
who were treated for a patent ductus arteriosus (PDA) with indomethacin or ibuprofen, we 
investigated whether platelet counts before or during pharmacological treatment had an 
impact on the successful closure of a hemodynamically significant PDA. The effects of other 
factors, such as sepsis, preeclampsia, gestational age, BW, and gender, were also evaluated.
results: Platelet counts before initiation of pharmacological PDA treatment did not differ 
between infants with later treatment success or failure. However, we found significant asso-
ciations between low platelet counts during pharmacological PDA therapy and treatment 
failure (p < 0.05). Receiver operating characteristic (ROC) curve analysis showed that platelet 
counts after the first, and before and after the second cyclooxygenase inhibitor (COXI) cycle 
were significantly associated with treatment failure (area under the curve of >0.6). However, 
ROC curve analysis did not reveal a specific platelet cutoff-value that could predict PDA 
treatment failure. Multivariate logistic regression analysis showed that lower platelet counts, 
a lower BW, and preeclampsia were independently associated with COXI treatment failure.
conclusion: We provide further evidence for an association between low platelet counts 
during pharmacological therapy for symptomatic PDA and treatment failure, while plate-
let counts before initiation of therapy did not affect treatment outcome.
Keywords: preterm infant, ibuprofen, indomethacin, patent ductus arteriosus, platelets, ductal closure
Abbreviations: BW, birth weight; CBC, complete blood count; COX, cyclooxygenase; COXI, cyclooxygenase inhibitor; CRIB, 
clinical risk indek for babies; DA, ductus arteriosus; DOL, days of (postnatal) life; ELBW, extremely low birth weight infant; GA, 
gestational age; PDA, patent ductus arteriosus; hsPDA, hemodynamically significant PDA; NICU, neonatal intensive care unit; 
NSAID, non-steroidal anti-inflammatory drug; ROC, receiver operating characteristic; VLBW, very low birth weight infant.
2Sallmon et al. Platelets and Pharmacological DA Closure
Frontiers in Pediatrics | www.frontiersin.org March 2018 | Volume 6 | Article 41
inTrODUcTiOn
Ductus arteriosus (DA) closure is an important step during the 
transition from fetal to extrauterine neonatal life. Failure of spon-
taneous DA closure in immature infants can be associated with 
several complications such as left ventricular volume overload, 
pulmonary edema, and impairment of lung compliance (1). 
However, due to a high spontaneous closure rate and a favorable 
outcome of infants who were discharged home with a persistently 
patent DA, it is controversial which patent ductus arteriosus 
(PDAs) require treatment (2). The aforementioned associations 
between adverse outcomes and a large and significant PDA 
provide the rationale for many clinicians to initiate treatment 
for hemodynamically significant PDAs (hsPDA) (3). The current 
mainstay of therapy is the administration of the cyclooxygenase 
(COX) inhibitors ibuprofen or indomethacin. These drugs act by 
inhibiting COX involved in producing prostaglandins E1 and E2 
that are known to promote ductal patency. The success rate of 
this pharmacological approach, however, varies and is difficult to 
predict for individual infants (1, 3).
In mice, platelet-triggered ductal sealing and subsequent 
vascular remodeling appears to be an important mechanism 
for definite DA closure (4). Murine platelets are recruited to the 
endothelium of the DA soon after birth, and platelet dysfunction 
or defective platelet formation was found to result in persistently 
patent DA. The role of platelets for DA closure in humans, 
however, remains controversial, especially in preterm infants. An 
association between low platelet counts on the first day of life and 
PDA has been described in several retrospective analyses (4–7). 
However, similar analyses failed to confirm these findings (8–13). 
Two recent meta-analyses indicated weak, but significant, asso-
ciations between hsPDA and thrombocytopenia on the first day 
of life and pre-treatment thrombocytopenia and pharmacological 
treatment failure, respectively (14, 15).
However, data from these studies on platelet counts during 
and just before initiation of therapy by day of life 4 or later 
are sparse in the reported investigations (15, 16). We herein 
analyzed whether platelet counts before initiation and during 
pharmacological PDA therapy are associated with treatment 
failure in a large cohort of very low birth weight infant (VLBW) 
infants.
MaTerials anD MeThODs
Patients
This retrospective cohort study was conducted at the neonatal 
intensive care units (NICUs) in the Department of Neonatology, 
Campus Virchow-Klinikum and Campus Mitte, Charité 
University Medical Center, Berlin Germany (1998–2008). All 
VLBW infants born in the respective period were included if 
they had received pharmacological treatment for hsPDA. Platelet 
counts before initiation of therapy, after the first, and before and 
after a second or third treatment cycle (if administered) were 
recorded, and the incidence of treatment success in the different 
groups was calculated. The clinical risk index for babies (CRIB) 
was calculated and parental consent for data collection was 
obtained after patient admission to the NICUs.
PDa Diagnosis/algorithm for PDa 
intervention
Infants were examined for hsPDA on days of (postnatal) life 
(DOL) 4–5 and when clinically indicated. Echocardiographic 
evaluation included shunt direction of a PDA in color Doppler 
mode (high upper parasternal short axis) as well as the minimal 
internal ductal diameter of three to five measurements taken 
in B-mode. The left atrium to aortic root (LA/Ao) ratio was 
measured by M-mode (parasternal long axis). The Doppler 
measurement of the resistance index in the anterior cerebral 
artery was done at the same time. Examinations were performed 
as previously described (8).
Cyclooxygenase inhibitor (COXI) treatment was initiated 
in all VLBW infants with an hsPDA. A PDA with left-to-right 
shunt was considered hemodynamically significant if (i) a res-
piratory set back with a supplemental oxygen requirement >30% 
and/or mechanical ventilation, (ii) a LA/Ao ratio ≥1.4 in the 
echocardiogram and/or (iii) ductal diameter ≥2.5  mm, and/or 
(iv) a decreased end-diastolic flow in the anterior cerebral artery 
with a resistance index ≥0.85 in the cerebral ultrasound were 
present. There has been no substantial change in the clinical and 
echocardiographic criteria used to determine the need for PDA 
intervention during the study period.
cOXi Therapy
None of the infants received treatment before an echocardiogram 
was performed. Infants received indomethacin or ibuprofen 
(Pedea®) exactly as previously described in detail (including dos-
ing, duration, etc.) (8). Successful response to COXI treatment was 
defined as absent ductal shunt flow 24–48 h after therapy, all other 
cases were defined as COXI treatment failure. Echocardiographic 
reassessment was performed after each therapy cycle.
statistics
Normality was tested by Kolmogorov–Smirnov test. Comparisons 
between groups were made by Kruskal–Wallis or Mann–Whitney 
U-test as appropriate for continuously scaled data and by chi-
square test for categorical data. p Values <0.05 were considered 
statistically significant. Statistical analyses, including multivariate 
logistic regression and receiver operating characteristic (ROC) 
curve analyses, were carried out using the IBM SPSS Statistics 
19 software.
resUlTs
incidence of PDa and Treatment success 
rates
Out of a total of 1,641 VLBW infants, we included 471 patients 
(28.7%) who were treated with COXI for hsPDA in the respective 
period (including 353 extremely low birth weight infant infants, 
Figure  1). Demographics of the patient cohort are shown in 
Table  1. The first COXI course was permanently successful in 
48.8% (230/471) of all VLBW infants. Of note, although 332 
infants (70.5%) achieved initial DA closure after the first COXI 
course, 102 infants developed reopening of their PDA after 
the first treatment course. Out of the remaining 241 infants, 
FigUre 1 | Flowchart: study population. Treatment with COX inhibitors was considered successful, if no further PDA therapy was required. COX, cyclooxygenase; 
hsPDA, hemodynamically significant PDA; PDA, patent ductus arteriosus; VLBW, very low birth weight (<1,500 g).
TaBle 1 | Characteristics of VLBW infants undergoing pharmacological 
treatment by cyclooxygenase inhibitors (COXI) for hemodynamically significant 
patent ductus arteriosus.
VlBW infants cOXi Total cOXi success cOXi Failure
N (%) 471 (100) 299 (63.5) 172 (36.5)
Female (n, %) 208 (44) 123 (41.1) 85 (49.4)
Birth weight (BW) (g) 867 (270–1.490) 875 (442–1.490) 749 (270–1.480)**
Gestational age 
(weeks)
26 (23–34) 26 (23–34) 25 (23–34)**
Twins (n, %) 125 (26.5) 78 (26.1) 47 (27.3)
Triplets (n, %) 25 (5.3) 16 (5.4) 9 (5.2)
Quadruplets (n, %) 3 (0.6) 1 (0.3) 2 (1.2)
Apgar 5 min 7 (1–9) 7 (1–9) 7 (1–9)
CRIB score 6 (0–17) 5 (0–17) 7 (0–17)**
Preeclampsia (n, %) 60 (12.7) 45 (15.1) 15 (8.7)*
Sepsis (n, %) 417 (88.5) 253 (84.6) 164 (95.3)*
Data are numbers (percentages) or median (range). In the top row, data in parentheses 
represent percentages referring to the total number of 471 included VLBW preterm 
infants (horizontal comparison within the first row). For all other data shown, 
percentages in parentheses refer to the total number in the upper first row of the same 
column (vertical comparison within the same column). Statistically significant values are 
given in bold (*p < 0.05; **p < 0.001).
VLBW, very low birth weight infant (<1,500 g); COXI, cyclooxygenase inhibitor 
(indomethacin or ibuprofen); CRIB, clinical risk index for babies.
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174 received a second, 33 a third, and 3 a fourth COXI course 
(Figure 1). In total, 299/471 infants (63.5%) achieved permanent 
ductal closure by pharmacological treatment, while 147 (31.2%) 
infants underwent secondary ligation. Nine patients (1.9%) were 
discharged home with a hsPDA, 6 (1.3%) died, and 10 (2.1%) 
experienced spontaneous PDA closure before a subsequent treat-
ment cycle was initiated. Of note, treatment success rates between 
the infants that initially received indomethacin or ibuprofen were 
not significantly different (p > 0.05).
Platelet counts before initiation and 
during Therapy and Treatment success 
rates
The platelet counts before initial pharmacological treatment 
did not differ significantly between infants with and infants 
without successful treatment. However, the first platelet counts 
after completion of the first COXI course differed significantly 
between infants with initial treatment success and failure 
(p < 0.001). Similar results were obtained for the platelet counts 
just before (p < 0.05) and after the second COXI cycle (p < 0.05, 
Table 2). Trends toward higher platelet counts in the treatment 
TaBle 2 | Platelet numbers in very low birth weight infants treated 
for hemodynamically significant PDA before and after each course of 
cyclooxygenase inhibitors.
cOXi success cOXi failure Time point (day of life)
Platelet counts before 1st cOXi cycle
Median 201,000 196,000 3
Minimum 27,000 11,000 1
Maximum 608,000 531,000 52
Platelet counts after 1st cOXi cycle
Median 308,000 220,000** 11
Minimum 19,000 35,000 3
Maximum 812,000 633,000 60
Platelet counts before 2nd cOXi cycle
Median 309,000 233,000* 14
Minimum 56,000 12,000 4
Maximum 580,000 497,000 63
Platelet counts after 2nd cOXi cycle
Median 289,000 198,000* 19
Minimum 31,000 24,000 7
Maximum 598,000 634,000 52
Platelet counts before 3rd cOXi cycle
Median 354,000 200,000 20
Minimum 96,000 13,000 10
Maximum 631,000 502,000 66
Platelet counts after 3rd cOXi cycle
Median 328,500 181,000 30
Minimum 105,000 30,000 14
Platelet counts are given in number/μL. Statistically significant differences between 
treatment success and failure are given in bold (*p < 0.05; **p < 0.001).
COXI, cyclooxygenase inhibitor.
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success group were also seen before and after the third course of 
COXI treatment. However, these results did not reach statistical 
significance due to a lower n number.
rOc curve and logistic regression 
analyses
Next, we performed a ROC curve analysis which showed a 
significant association between platelet counts after the first 
COXI cycle and treatment failure with an area under the curve 
(AUC) of 0.617 and a confidence interval (CI) of 0.560–0.674. 
However, the form of the curve indicated no specific cutoff 
that could be used to predict treatment failure below a specific 
platelet count (Figure 2). Of note, similar results were obtained 
for platelet counts before and after the second COXI cycle (data 
not shown).
In this study, preeclampsia was associated with significantly 
lower platelet counts at birth (p < 0.001). Similarly, infants with 
sepsis, defined by elevated systemic markers of inflammation 
(IL-6 and/or CRP) and the use of antibiotics, showed a non-
significant trend toward lower platelet counts before initiation 
of therapy. Multivariate logistic regression analysis showed that 
higher platelet counts after the first COXI cycle were indepen-
dently associated with treatment success, while sepsis, and gender 
had no significant effect (Table 3). In addition, birth weight (BW) 
[or gestational age (GA)], and preeclampsia were also independ-
ent predictors of treatment success rates.
DiscUssiOn
The role of platelets during closure of the DA is subject to 
ongoing debates. While experimental data suggest that platelets 
are involved in spontaneous ductal closure (4), the clinical 
implications of these findings are controversial especially in very 
immature infants. In our previous study on 1,350 VLBW infants, 
we found no association between platelet counts within the first 
24 h after birth and spontaneous ductal closure. We also did not 
find an association between platelet count on DOL 1 and a later 
treatment failure. However, sepsis, male gender, a lower BW, or 
GA were risk factors for hsPDA development (8). Similarly, Shah 
et al. assessed serial platelet counts (DOL 1–7) in preterm infants 
born <28 weeks of gestation and PDA closure rates (n = 497). 
Neither high nor low platelet numbers had an impact on per-
manent DA closure. However, in this study, all infants received 
prophylactic indomethacin starting on DOL 1 (17). Data on the 
platelet counts during and just before initiation of symptomatic 
PDA therapy by day of life 4 or later are sparse in the reported 
investigations (15, 16).
In this study, we addressed this issue by investigating serial 
platelet counts in relation to PDA treatment success, which 
provides a differential picture on the influence of platelet counts 
before and after each COXI cycle and its success. We were able 
to demonstrate, that platelet counts just before initiation of phar-
macological PDA therapy (median DOL 3) were not associated 
with treatment failure. However, we found statistically significant 
associations between platelet counts during COXI therapy and 
the respective success rates. Furthermore, a lower BW, a lower 
GA, and a higher CRIB score were significantly associated with 
treatment failure of COXI therapy in this cohort. Interestingly, 
male gender, which others and we previously reported to be an 
independent risk factor for development of an hsPDA, was not 
significantly associated with treatment failure rates. Similarly, 
preeclampsia, which is known to affect platelet numbers 
(18, 19), was significantly associated with COXI therapy failure. 
Interestingly, sepsis/infection had no effect on treatment success 
rates, which is likely due to the less strict definition used in this 
study (elevated systemic markers of infection, use of antibiotics).
The available data on platelet counts and their implications 
for DA closure and PDA treatment success are controversial. The 
reported heterogeneity of previous studies might be explained 
by different definitions of hsPDA, different echocardiographic 
screening protocols (parameters and time points), and by 
different treatment protocols (prophylactic vs. symptomatic 
treatment). This study cannot definitively answer the question of 
how clinically relevant low platelet counts are for ductal closure 
in human preterm infants. However, it provides evidence for an 
association between low platelet counts during COXI therapy 
initiated between DOL 3 and 5 for symptomatic PDA and treat-
ment failure. Logistic regression analysis showed a significant 
albeit weak independent effect of platelet counts during PDA 
therapy on success rates. These findings currently do not change 
clinical practice as no clear cutoff value that was associated with 
treatment failure could be established.
Besides platelet numbers, thrombocyte function might play 
a role during DA closure. The most immature infants are also 
TaBle 3 | Logistic regression analysis for prediction of COXI treatment success.
B se Wald df significance exp(B)
Gestational age*** 0.294 0.073 16.140 1 <0.001 1.342
PLT after 1st COXI 
cycle***
0.003 0.001 12.629 1 <0.001 1.003
Preeclampsia* −0.867 0.414 4.379 1 0.036 0.420
Sepsis/infection 0.315 0.464 0.460 1 0.497 1.370
Male gender −0.306 0.237 1.669 1 0.196 0.736
Constant −0.922 1.967 12.380 1 0.000 0.001
381/471 (80.9%) of cases with a complete dataset were included in this analysis. 
Of note, sepsis/infection was defined by elevated markers of infection and antibiotic 
therapy. Significant factors (*p < 0.05, ***p < 0.001) are listed in bold.
B, coefficient for the constant; Wald, Wald chi-square test; df, degree of freedom; 
Exp(B), exponent B; PLT, platelet number; COXI, cyclooxygenase inhibitor.
FigUre 2 | Receiver operating characteristic (ROC) curve analysis. The ROC curve analysis shows a significant association between platelet counts after the first 
cyclooxygenase inhibitor (COXI) cycle and treatment failure with an area under the curve (AUC) of 0.617 and a confidence interval (CI) of 0.560–0.674. However, the 
form of the curve indicated no specific cutoff that could be used to predict treatment failure below a specific platelet count. Of note, similar results were obtained for 
platelet counts before and after the second COXI cycle (data not shown). For comparison, we also included platelet counts before the first COXI dose (AUC 0.513; 
CI 0.453–0.574), gestational age (AUC 0.703; CI 0.647–0.759), and birth weight (AUC 0.652; CI 0.594–0.710).
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most likely to have impaired platelet function (e.g., due to sepsis, 
immaturity, or medication). Therefore, future prospective investi-
gations should include parameters of platelet function (20), espe-
cially in infants receiving non-steroidal anti-inflammatory drugs 
(NSAIDs), which are known to potentially alter platelet function. 
In regard to this, Kahvecioglu et al. reported longer collagen-ADP 
times in infants with hsPDA (21). Other authors have suggested 
that parameters such as platelet mass or mean platelet volume 
might be important for DA closure (6, 11, 12, 21, 22).
NSAIDs are standard of care in closing a hsPDA in preterm 
infants (3). Overall, we observed successful ductal closure after 
initial therapy in 63.5% of all VLBW infants, respectively, which 
is consistent with the ranges reported in the literature (1). In 
the patients analyzed, NSAIDs were usually withheld if platelet 
counts were <50,000/μL. A total of 55 infants received platelet 
transfusions during COXI treatment, which did not influence the 
treatment success rates. NSAID treatment of infants with moder-
ate thrombocytopenia (50,000–100,000/μL) was considered save. 
However, this assumption was based on the only randomized 
controlled trial on platelet transfusion thresholds performed to 
date. Andrew et al. randomized 152 thrombocytopenic infants to 
receive platelet transfusions for any platelet count <150,000/μL or 
for a platelet count <50,000/μL (or clinical indications) targeting 
a primary outcome of IVH. These investigators found no sig-
nificant differences in frequency or severity of IVH between the 
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two groups (23). However, Brunner et al. reported an increased 
risk for intracerebral bleeding in VLBW infants with moderate 
thrombocytopenia that were treated with COXI (24).
These findings illustrate the critical need for well-designed 
prospective randomized trials that investigate the outcome of 
thrombocytopenic neonates and the safety of different platelet 
transfusion thresholds (19, 25, 26). Furthermore, trials investi-
gating the optimal PDA management (indication for treatment, 
optimal dosing of NSAIDs, etc.) are essential to improve out-
comes, of the most immature infants.
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